Renal Anemia Treatment - Global Strategic Business Report

The global market for Renal Anemia Treatment was estimated at US$7.8 Billion in 2024 and is projected to reach US$10.5 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Renal Anemia Treatment market.

Global Renal Anemia Treatment Market - Key Trends & Drivers Summarized

Why Is Renal Anemia Emerging as a Critical Comorbidity in Chronic Kidney Disease?

Renal anemia, a common complication of chronic kidney disease (CKD), is primarily caused by the kidneys' reduced ability to produce erythropoietin, the hormone essential for red blood cell synthesis. As CKD progresses, impaired erythropoietin production leads to decreased hemoglobin levels, causing fatigue, cardiovascular strain, and diminished quality of life. The prevalence of renal anemia increases with the severity of CKD, affecting nearly 90% of patients in stage 5. This correlation has brought renewed clinical focus on early detection and integrated management of anemia in CKD to prevent long-term systemic complications.

Managing renal anemia is particularly challenging because of the interplay between iron deficiency, inflammation, and erythropoiesis-stimulating agent (ESA) resistance. Inflammation and elevated hepcidin levels restrict iron mobilization, further suppressing erythropoiesis. Cardiovascular risks associated with high ESA doses and iron overload have also influenced the evolution of treatment protocols. These complexities have prompted nephrologists to favor individualized treatment approaches that balance efficacy, safety, and quality of life. The increasing global burden of CKD-linked to aging populations, diabetes, and hypertension-is fueling the expansion of the renal anemia treatment market.

How Are Treatment Modalities Evolving With Technological and Clinical Innovations?

Historically, renal anemia has been treated using ESAs and intravenous (IV) iron supplementation. First-generation ESAs such as epoetin alfa and darbepoetin alfa became standard therapy, stimulating erythropoiesis in dialysis and non-dialysis patients. However, long-term data revealing elevated cardiovascular risks with high ESA doses, particularly in non-dialysis CKD patients, have driven the development of safer and more physiologic alternatives. One such innovation is the class of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which stimulate endogenous erythropoietin production at physiological levels while improving iron utilization.

Approved HIF-PHIs such as roxadustat, daprodustat, and vadadustat are oral agents offering a non-injectable alternative to ESAs. These drugs have demonstrated comparable efficacy in increasing hemoglobin levels, with additional benefits in reducing hepcidin and improving iron metabolism. They are especially suited for non-dialysis CKD patients who might otherwise face adherence issues with injectable ESAs. IV iron formulations have also advanced, with newer agents such as ferric carboxymaltose and ferric derisomaltose offering larger single-dose administration and reduced infusion frequency. The combination of these innovations is shifting treatment paradigms away from ESA-centric regimens toward more holistic and targeted approaches.

Which Patient Populations and Healthcare Settings Are Driving Demand Differentiation?

Dialysis-dependent patients form the core segment of the renal anemia treatment market. Hemodialysis facilities maintain consistent ESA and IV iron protocols due to the high anemia burden in this population. However, the non-dialysis CKD population, which is substantially larger in absolute numbers, is emerging as a major area of unmet need. These patients are less likely to be monitored regularly, and logistical challenges associated with injectable therapies often delay anemia intervention. Oral HIF-PHIs are being positioned as game changers for this segment due to their convenience and better adherence potential.

Pediatric CKD patients represent a niche but significant subset. Anemia management in this population requires weight-adjusted dosing and heightened vigilance for long-term adverse effects, driving demand for safer formulations and long-acting agents. Geographically, high-growth markets include China, India, and Latin America, where CKD incidence is rising and healthcare systems are expanding access to dialysis and nephrology care. In these regions, biosimilars and cost-effective oral therapies are gaining traction. Meanwhile, North America and Europe continue to invest in treatment innovation and care integration, with reimbursement frameworks adapting to support new therapeutic classes.

What Factors Are Driving the Growth of the Renal Anemia Treatment Market?

The growth in the renal anemia treatment market is driven by the global rise in CKD prevalence, clinical adoption of novel therapeutics such as HIF-PHIs, improved anemia screening programs, and expanding dialysis infrastructure. Aging populations, rising diabetes and hypertension rates, and environmental contributors to kidney disease are steadily increasing the global patient pool. This is translating into higher demand for long-term anemia management, particularly in pre-dialysis and elderly populations.

Regulatory approvals for oral HIF-PHIs across major markets are enhancing treatment accessibility and patient adherence. Health systems are gradually adopting value-based care models that prioritize early anemia intervention to reduce cardiovascular complications and hospitalizations. Technological advancements in point-of-care hemoglobin monitoring and iron profiling are improving diagnosis and real-time treatment adjustment. Reimbursement reforms, particularly in the U.S. under the ESRD Treatment Choices Model, are also incentivizing better anemia control in dialysis centers. Together, these trends are reshaping a market that was once dominated by injectables into one that is more diverse, patient-centric, and innovation-driven.

Scope Of Study:

The report analyzes the Renal Anemia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Treatment (Medication Treatment, Dietary Supplement Treatment); Disease (Normocytic Anemia Disease, Microcytic Anemia Disease, Macrocytic Anemia Disease)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Medication Treatment segment, which is expected to reach US$6.7 Billion by 2030 with a CAGR of a 6.2%. The Dietary Supplement Treatment segment is also set to grow at 3.5% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.1 Billion in 2024, and China, forecasted to grow at an impressive 8.4% CAGR to reach $2.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Renal Anemia Treatment Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Renal Anemia Treatment Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Renal Anemia Treatment Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., Asahi Kasei Corporation, Astellas Pharma Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Renal Anemia Treatment market report include:

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Amgen Inc.
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• AstraZeneca plc
• Baxter International Inc.
• Bayer AG
• B. Braun Melsungen AG
• Boehringer Ingelheim GmbH
• CSL Vifor
• DaVita Inc.
• Eli Lilly and Company
• FibroGen, Inc.
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline (GSK) plc
• Japan Tobacco Inc.
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Roche (F. Hoffmann-La Roche Ltd.)
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.